Customs procedures: new US problems for the German pharmaceutical industry?

The United States has initiated an investigation into Germany’s practices regarding the payment for innovative pharmaceutical products, alleging that Germany has been persistently underpaying for such medications. This move comes under Section 301 of the Trade Act of 1974, a provision that allows the U.S. to investigate and potentially impose tariffs on foreign goods deemed to be unfair or discriminatory in trade practices. According to U.S. Trade Representative Jamieson Greer, the investigation aims to assess whether Germany’s payment practices are unreasonable or discriminatory and whether they burden or restrict U.S. commerce.

Greer emphasized that President Donald Trump has consistently argued that American patients should not bear an undue share of the costs associated with global pharmaceutical research and development. He expressed particular concern over reports suggesting that Germany is accelerating legislation aimed at reducing its expenditures on innovative pharmaceuticals. This legislation is part of broader healthcare reforms being considered by the German government, which seeks to address a projected deficit in statutory health insurance funds by implementing cost-saving measures worth over €16 billion. These reforms include changes to how pharmaceutical products are priced and reimbursed within the German healthcare system.

The U.S. investigation follows months of discussions between U.S. officials and their German counterparts, during which efforts were made to resolve the issue without resorting to formal trade action. However, these talks apparently failed to yield a resolution. As part of the process, the U.S. Trade Representative’s office will accept written comments starting on June 25, and a public hearing is scheduled for September. The potential implications of this investigation could extend beyond mere diplomatic discourse, as the U.S. has previously threatened to impose tariffs on imports from countries perceived as freeloading on American innovation.

Germany’s proposed healthcare reforms aim to balance the financial pressures facing its statutory health insurance system while ensuring continued access to innovative medicines. The reforms involve a shift away from dynamic discounts on pharmaceutical products, which vary based on negotiations, toward a fixed discount model. This change is intended to provide greater predictability for pharmaceutical companies while contributing to the reduction of the projected deficit. However, the reform has raised concerns among industry stakeholders, including pharmaceutical firms that have indicated they might scale back investments in Germany due to the uncertainty surrounding future reimbursement rates.

The U.S. has long maintained that American consumers pay disproportionately high prices for pharmaceuticals compared to other countries, arguing that this disparity enables the U.S. to finance a significant portion of global pharmaceutical research and development. A 2024 report by the RAND Corporation highlighted that U.S. prescription drug prices average 2.78 times those in 33 other countries, with even wider gaps observed for branded medications. From the perspective of the U.S., countries like Germany, France, and Canada benefit from lower drug prices set by centralized state regulations, effectively allowing them to avoid bearing the full cost of pharmaceutical innovation.

In response to these concerns, former President Trump issued executive orders aimed at compelling pharmaceutical companies to offer “most favored nation” pricing in the U.S., aligning prices with those in other countries. Some companies complied by lowering certain drug prices while also committing to new investments in the U.S. to mitigate the risk of sanctions. However, the current administration continues to press for a resolution that ensures fair compensation for American pharmaceutical manufacturers without disrupting access to essential medicines for German patients.

The situation underscores the complex interplay between national healthcare policies and international trade relations. While Germany seeks to manage its healthcare budget amid rising costs, the U.S. remains focused on ensuring that its pharmaceutical sector receives adequate returns for its research and development efforts. The outcome of the ongoing investigation could influence not only bilateral trade dynamics but also shape the future of global pharmaceutical pricing strategies. As both sides continue to negotiate, the challenge lies in finding a compromise that addresses the concerns of all parties involved without compromising patient access to life-saving treatments.